South Korea’s biotechnology leader, Samsung Biologics, has announced plans to acquire Swiss peptide drug manufacturer PolyPeptide Group in a deal valued at approximately $1.8 billion. The proposed acquisition represents the company’s largest overseas investment to date and reflects its strategy to broaden its capabilities in the rapidly growing pharmaceutical manufacturing market.
Strengthening Presence in Advanced Biopharmaceuticals
The planned acquisition marks an important milestone for Samsung Biologics as it expands beyond its traditional expertise in antibody manufacturing into peptide-based therapeutics.
Peptide drugs are gaining increasing attention within the pharmaceutical industry due to their potential applications in treating a wide range of medical conditions, including metabolic disorders, cancer, and rare diseases. By adding peptide manufacturing capabilities, Samsung Biologics aims to offer a more comprehensive portfolio of contract development and manufacturing services to global pharmaceutical companies.
Expanding Beyond Antibodies
Samsung Biologics has established itself as one of the world’s leading contract development and manufacturing organizations (CDMOs), specializing in the production of biologic medicines.
With the acquisition of PolyPeptide Group, the company plans to diversify its offerings beyond monoclonal antibodies and antibody-drug conjugates (ADCs), entering another high-growth segment of the biopharmaceutical industry.
The broader product portfolio is expected to strengthen the company’s ability to support drug developers throughout multiple stages of pharmaceutical production.
Details of the Proposed Transaction
Under the proposed agreement, Samsung Biologics intends to acquire all outstanding shares of PolyPeptide Group through an all-cash public tender offer.
The offer values the Swiss company at approximately 1.46 billion Swiss francs, representing a premium over its market value before reports of the potential acquisition emerged.
The transaction remains subject to several conditions, including shareholder approval, regulatory clearances, and other customary closing requirements. Completion is expected toward the end of 2026 if all necessary approvals are secured.
Strategic Benefits
The acquisition is expected to provide several strategic advantages for Samsung Biologics.
By integrating peptide manufacturing into its operations, the company can better meet growing demand for specialized pharmaceutical production while expanding its customer base across the global biotechnology sector.
The move also supports Samsung Biologics’ long-term ambition to become a fully integrated manufacturing partner capable of serving a broader range of biologic and peptide therapies.
Growing Demand for Peptide Medicines
Interest in peptide therapeutics has increased significantly in recent years as pharmaceutical companies invest in innovative treatments for chronic diseases and complex medical conditions.
The expanding market has created new opportunities for manufacturers with specialized production capabilities, making peptide development an increasingly attractive area for investment.
As more peptide-based medicines advance through clinical development, demand for reliable manufacturing partners is expected to continue growing.
Strengthening Global Competitiveness
The proposed acquisition also reinforces Samsung Biologics’ international expansion strategy. Establishing a stronger presence in Europe through the acquisition of a Swiss manufacturer could enhance the company’s global production network and improve its ability to serve customers across multiple regions.
The investment demonstrates the company’s commitment to remaining competitive in an industry where scale, technological expertise, and manufacturing flexibility are becoming increasingly important.
Looking Ahead
Samsung Biologics’ planned acquisition of PolyPeptide Group signals a significant step in the company’s evolution as a global biopharmaceutical manufacturing leader. By expanding into peptide therapeutics, the company is positioning itself to capitalize on one of the fastest-growing segments of the pharmaceutical industry.
If completed, the acquisition could strengthen Samsung Biologics’ global capabilities, diversify its service offerings, and support its long-term strategy of becoming a comprehensive partner for the development and manufacturing of next-generation medicines.